General form of registration statement for all companies including face-amount certificate companies

Segment Reporting (Tables)

v3.7.0.1
Segment Reporting (Tables)
9 Months Ended 12 Months Ended
Mar. 31, 2017
Jun. 30, 2016
Segment Reporting [Abstract]    
Schedule of Segment Reporting Information, by Segment [Table Text Block]
These segments are components of the Company about which separate financial information is available and regularly evaluated by the chief operating decision maker in deciding how to allocate resources and in assessing performance.
 
Three Months Ended March 31, 2017 (in thousands)
 
iBio, Inc.
 
iBio CMO
 
Eliminations
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues - external customers
 
$
-
 
$
37
 
$
-
 
$
37
 
Revenues – intersegment
 
 
283
 
 
361
 
 
(644)
 
 
-
 
Research and development
 
 
1,033
 
 
472
 
 
(369)
 
 
1,136
 
General and administrative
 
 
1,276
 
 
1,836
 
 
(275)
 
 
2,837
 
Operating loss
 
 
(2,026)
 
 
(1,910)
 
 
-
 
 
(3,936)
 
Interest expense
 
 
-
 
 
(481)
 
 
-
 
 
(481)
 
Interest and other income
 
 
8
 
 
4
 
 
-
 
 
12
 
Consolidated net loss
 
 
(2,018)
 
 
(2,387)
 
 
-
 
 
(4,405)
 
Total assets
 
 
20,573
 
 
32,680
 
 
(12,555)
 
 
40,698
 
Fixed assets, net
 
 
8
 
 
25,786
 
 
-
 
 
25,794
 
Intangible assets, net
 
 
1,895
 
 
-
 
 
-
 
 
1,895
 
Depreciation expense
 
 
1
 
 
336
 
 
-
 
 
337
 
Amortization of intangible assets
 
 
88
 
 
-
 
 
-
 
 
88
 
 
Three Months Ended March 31, 2016 (in thousands)
 
iBio, Inc.
 
iBio CMO *
 
Eliminations
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues - external customers
 
$
371
 
$
8
 
$
-
 
$
379
 
Revenues – intersegment
 
 
-
 
 
129
 
 
(129)
 
 
-
 
Research and development
 
 
951
 
 
226
 
 
(129)
 
 
1,048
 
General and administrative
 
 
1,532
 
 
871
 
 
-
 
 
2,403
 
Operating loss
 
 
(2,112)
 
 
(960)
 
 
-
 
 
(3,072)
 
Interest expense
 
 
-
 
 
(323)
 
 
-
 
 
(323)
 
Interest and other income
 
 
8
 
 
2
 
 
-
 
 
10
 
Consolidated net loss
 
 
(2,104)
 
 
(1,281)
 
 
-
 
 
(3,385)
 
Total assets
 
 
11,015
 
 
39,690
 
 
(40)
 
 
50,665
 
Fixed assets, net
 
 
13
 
 
25,762
 
 
-
 
 
25,775
 
Intangible assets, net
 
 
2,139
 
 
-
 
 
-
 
 
2,139
 
Depreciation expense
 
 
2
 
 
259
 
 
-
 
 
261
 
Amortization of intangible assets
 
 
92
 
 
-
 
 
-
 
 
92
 
 
Nine Months Ended March 31, 2017 (in thousands)
 
iBio, Inc.
 
iBio CMO
 
Eliminations
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues - external customers
 
$
161
 
$
86
 
$
-
 
$
247
 
Revenues – intersegment
 
 
695
 
 
950
 
 
(1,645)
 
 
-
 
Research and development
 
 
2,733
 
 
1,240
 
 
(968)
 
 
3,005
 
General and administrative
 
 
3,864
 
 
4,470
 
 
(677)
 
 
7,657
 
Operating loss
 
 
(5,741)
 
 
(4,674)
 
 
-
 
 
(10,415)
 
Interest expense
 
 
-
 
 
(1,447)
 
 
-
 
 
(1,447)
 
Interest and other income
 
 
35
 
 
18
 
 
-
 
 
53
 
Consolidated net loss
 
 
(5,706)
 
 
(6,103)
 
 
-
 
 
(11,809)
 
Total assets
 
 
20,573
 
 
32,680
 
 
(12,555)
 
 
40,698
 
Fixed assets, net
 
 
8
 
 
25,786
 
 
-
 
 
25,794
 
Intangible assets, net
 
 
1,895
 
 
-
 
 
-
 
 
1,895
 
Depreciation expense
 
 
3
 
 
984
 
 
-
 
 
987
 
Amortization of intangible assets
 
 
264
 
 
-
 
 
-
 
 
264
 
 
Nine Months Ended March 31, 2016 (in thousands)
 
iBio, Inc.
 
iBio CMO *
 
Eliminations
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues - external customers
 
$
665
 
$
8
 
$
-
 
$
673
 
Revenues – intersegment
 
 
-
 
 
129
 
 
(129)
 
 
-
 
Research and development
 
 
2,192
 
 
240
 
 
(129)
 
 
2,303
 
General and administrative
 
 
4,550
 
 
959
 
 
-
 
 
5,509
 
Operating loss
 
 
(6,077)
 
 
(1,062)
 
 
-
 
 
(7,139)
 
Interest expense
 
 
-
 
 
(323)
 
 
-
 
 
(323)
 
Interest and other income
 
 
24
 
 
2
 
 
-
 
 
26
 
Consolidated net loss
 
 
(6,053)
 
 
(1,383)
 
 
-
 
 
(7,436)
 
Total assets
 
 
11,015
 
 
39,690
 
 
(40)
 
 
50,665
 
Fixed assets, net
 
 
13
 
 
25,762
 
 
-
 
 
25,775
 
Intangible assets, net
 
 
2,139
 
 
-
 
 
-
 
 
2,139
 
Depreciation expense
 
 
4
 
 
259
 
 
-
 
 
263
 
Amortization of intangible assets
 
 
274
 
 
-
 
 
-
 
 
274
 
   
*
iBio CMO commenced operations in December 2015
Geographic segments are components of an enterprise about which separate financial information is available and regularly evaluated by the chief operating decision maker in deciding how to allocate resources and in assessing performance.
 
Year ended June 30, 2016
 
United States
 
Brazil
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
Net revenues
 
$
948
 
$
-
 
$
948
 
Research and development expenses
 
 
3,156
 
 
-
 
 
3,156
 
General and administrative expenses
 
 
7,663
 
 
22
 
 
7,685
 
Operating loss
 
 
(9,871)
 
 
(22)
 
 
(9,893)
 
Interest expense
 
 
(807)
 
 
-
 
 
(807)
 
Interest and other income
 
 
43
 
 
-
 
 
43
 
Consolidated net loss
 
 
(10,635)
 
 
(22)
 
 
(10,657)
 
Total assets
 
 
51,580
 
 
20
 
 
51,600
 
Fixed assets, net
 
 
25,574
 
 
-
 
 
25,574
 
Intangible assets, net
 
 
2,092
 
 
-
 
 
2,092
 
Depreciation expense
 
 
575
 
 
2
 
 
577
 
Amortization of intangible assets
 
 
363
 
 
-
 
 
363
 
 
Year ended June 30, 2015
 
United States
 
Brazil
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
Net revenues
 
$
1,851
 
$
-
 
$
1,851
 
Research and development expenses
 
 
3,495
 
 
-
 
 
3,495
 
General and administrative expenses
 
 
4,929
 
 
93
 
 
5,022
 
Operating loss
 
 
(6,573)
 
 
(93)
 
 
(6,666)
 
Interest expense
 
 
-
 
 
-
 
 
-
 
Interest and other income
 
 
41
 
 
-
 
 
41
 
Consolidated net loss
 
 
(6,532)
 
 
(93)
 
 
(6,625)
 
Total assets
 
 
12,448
 
 
46
 
 
12,494
 
Fixed assets, net
 
 
3
 
 
10
 
 
13
 
Intangible assets, net
 
 
2,360
 
 
-
 
 
2,360
 
Depreciation expense
 
 
3
 
 
2
 
 
5
 
Amortization of intangible assets
 
 
358
 
 
-
 
 
358